A 13-year-old boy was referred because of visual deterioration in his right eye. The visual acuity was two metres of counting fingers. Indirect ophthalmoscopy and biomicroscopy revealed exudative macular oedema as well as tumour-like telangiectatic vessels and exudation in temporal periphery.
A 13-year-old boy was referred because of visual deterioration in his right eye. The visual acuity was two metres of counting fingers. Indirect ophthalmoscopy and biomicroscopy revealed exudative macular oedema as well as tumour-like telangiectatic vessels and exudation in temporal periphery. With diagnosis of Coats' disease (stage II) confirmed by fluorescein angiography, three intravitreal injections of bevacizumab were performed at 6-week intervals. One year after the last injection, there was a significant resolution of macular oedema as well as visual acuity improvement to 20/20. This is the first case report in which a distinct improvement in macular oedema was observed with intravitreal bevacizumab in Coats' disease.
To read the full case click here
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.